by Stephen Levin
For the second year in a row, Medtronic Inc. created a stir at the TCT (Transcatheter Cardiovascular Therapeutics) conference...
Will Late Loss Debate Stifle Device Start-Up Innovation?
The failure of Medtronic's Endeavor stent to hit its primary clinical trial goals has again spurred debate over surrogate endpoints, a poetntially big issue for small companies.
More from Innovation
More from In Vivo
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.